The Procter & Gamble Company PG and Colgate-Palmolive Company CL are two of the world’s most established consumer staples companies, but their competitive strengths are built on different foundations.
PG operates a broad portfolio spanning beauty, grooming, health care, fabric and home care, and family care, supported by globally recognized brands and leading positions across numerous categories. Colgate, meanwhile, is more concentrated, with a particularly powerful presence in oral care alongside personal care, home care and pet nutrition. This difference in business mix shapes how the two companies compete for market share. PG relies on its scale, category breadth, innovation and premium brands to defend leadership across multiple consumer markets, while Colgate draws strength from its dominant global toothpaste franchise and deep oral-care expertise.
As consumer preferences, pricing dynamics and competitive intensity evolve, comparing their market positions offers a revealing look at two distinct routes to sustained brand leadership.
The Case for PG
Procter & Gamble’s investment case rests on the scale and resilience of a portfolio that spans 10 major product categories and seven regions. In fiscal 2026, nine of 10 categories held or grew organic sales, while five of 10 held or gained global share. Twenty-six of its top 50 category-country combinations held or grew share, and aggregate global share exited the year flat after improving in the second half.
Its strategy centers on product superiority, premium brand positioning, innovation and disciplined reinvestment. PG is leaning into faster-growing Beauty and Health segments, while strengthening core franchises such as Tide, Charmin and Bounty. Its consumer base skews somewhat toward households earning above $100,000, although the portfolio spans price points and pack sizes for more value-conscious shoppers.
E-commerce grew 6% year over year and reached 20% of sales, while AI-enabled brand building, data platforms and digital retail partnerships are being scaled to sharpen engagement and conversion.
The company’s fiscal 2026 organic sales rose more than 1%, core EPS increased 1% to $6.89 and productivity savings reached $2.8 billion before tax. PG also returned more than $15 billion to shareholders, while continuing to fund innovation, advertising and digital capabilities.
The Case for CL
Colgate’s investment case is anchored in its global scale, category leadership and diversified exposure across Oral Care, Personal Care, Home Care and Hill’s Pet Nutrition. In the second quarter of 2026, organic sales grew in four of five divisions and three of four categories, while emerging markets advanced in the mid-single digits, led by India, Brazil, Mexico and China. Hill’s also outperformed its category, with organic sales, excluding private label, rising 4% against a roughly flat U.S. category.
Colgate is leaning on premiumization, science-led innovation and disciplined revenue growth management. In Oral Care, premium products such as Optic White, Elmex and Meridol are central to share expansion, while Hill’s targets pet owners seeking veterinarian-backed, science-based nutrition.
Emerging markets broaden the demographic opportunity, with Colgate balancing accessible price points for value-conscious consumers against premium offerings for higher-income shoppers. Europe’s toothpaste strategy shows this positioning clearly, with super-premium offerings driving growth while Colgate remains under-indexed in premium segments globally, leaving room for further expansion.
Digital capability is becoming another competitive lever. Colgate is scaling Promo AI, omni-demand generation and agentic tools, while 70% of vice presidents have received advanced AI training. Financially, the free cash flow rose 18%, $1.4 billion was returned to shareholders, the gross margin expanded 100 basis points and advertising increased double digits, supporting brand investment without sacrificing profitability.
How Do Estimates Compare for PG & CL?
The Zacks Consensus Estimate for Procter & Gamble’s fiscal 2027 sales and EPS implies year-over-year growth of 1.8% and 1.5%, respectively. EPS estimates for fiscal 2027 have moved down by a penny in the past 30 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Colgate’s 2026 sales and EPS suggests year-over-year growth of 4.8% and 4.9%, respectively. EPS estimates for 2026 have moved up by a penny in the past 30 days.
Image Source: Zacks Investment Research
Consensus trends point to steadier but softer momentum for Procter & Gamble, with modest sales and earnings growth expectations and a slight downward EPS revision. Colgate shows comparatively stronger near-term momentum, supported by healthier projected sales and earnings growth and a recent upward EPS revision, signaling relatively firmer analyst confidence.
Price Performance & Valuation of Procter & Gamble, & Colgate
In the past year, PG shares have lost 4.2%, while the CL stock has risen 7.6%.
Image Source: Zacks Investment Research
Procter & Gamble is trading at a forward 12-month price-to-earnings multiple of 20.62X, below its median of 23.33X in the last five years. Colgate’s forward 12-month P/E multiple sits at 21.43X, below its median of 23.49X in the last five years.
Image Source: Zacks Investment Research
Share-price trends have diverged, with Procter & Gamble declining in the past year while Colgate has delivered positive returns. This suggests investors have recently shown greater confidence in Colgate’s growth trajectory and operating momentum, whereas PG’s slower growth profile and near-term cost pressures may have weighed on sentiment.
From a valuation standpoint, the figures provided indicate that both PG and Colgate are trading below their respective historical median forward P/E multiples. This suggests that current valuations are less demanding than their longer-term norms, potentially reflecting cautious expectations around consumer demand, inflation and earnings growth.
Conclusion
Taken together, the face-off favors Colgate. While Procter & Gamble offers unmatched scale, portfolio breadth and brand strength, Colgate currently shows stronger operating momentum, supported by premiumization, oral-care leadership, emerging-market growth and expanding digital capabilities. Its superior one-year share performance also reflects comparatively stronger market confidence.
Colgate’s earnings outlook further strengthens its case. Consensus estimates point to healthier sales and profit growth, while the recent upward earnings revision signals improving confidence in its earnings potential. PG’s growth outlook appears more subdued alongside a slight downward estimate revision. Overall, Colgate emerges as the stronger pick in this comparison.
Both Procter & Gamble and Colgate currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Procter & Gamble Company (The) (PG): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).